IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter

USD · NASDAQ:KARD
Issue Size
$400.00M
Price Range
$14.00 - $16.00
Shares
89.34M o/s · 25M offered
Listing Price
$16.25
Kardigan, Inc.
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.
The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure.
It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Change from offer price to today
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:KARD
Key valuation ratios and metrics
Historical financial performance
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | $24.00 | $27.00 | $23.60 | $25.90 | $25.90 | +1.90 | 1,376,100 |
| 2026-06-26 | $22.27 | $24.54 | $21.88 | $23.60 | $23.60 | +1.33 | 852,400 |
| 2026-06-25 | $22.28 | $23.88 | $21.19 | $22.58 | $22.58 | +0.30 | 298,900 |
| 2026-06-24 | $21.68 | $23.21 | $21.26 | $22.03 | $22.03 | +0.35 | 472,300 |
| 2026-06-23 | $22.96 | $24.86 | $21.50 | $22.24 | $22.24 | -0.72 | 548,400 |
| 2026-06-22 | $21.29 | $24.00 | $20.07 | $22.77 | $22.77 | +1.48 | 922,100 |
| 2026-06-18 | $16.25 | $23.75 | $16.25 | $22.00 | $22.00 | +5.75 | 5,844,400 |
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13G | Jun 29, 2026 | Filing |
| SCHEDULE 13D | Jun 29, 2026 | Filing |
| SCHEDULE 13D | Jun 25, 2026 | Filing |
| 8-K | Jun 23, 2026 | Current Report |
| 424B4 | Jun 18, 2026 | Prospectus |
| EFFECT | Jun 17, 2026 | Notice of Effectiveness |
| S-1MEF | Jun 17, 2026 | Registration adding securities to prior Form S-1 registration |
| S-8 | Jun 17, 2026 | Securities to be offered to employees in employee benefit plans |
| CERT | Jun 17, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Jun 15, 2026 | Registration of securities |
Contact and headquarters details
Key executives and officers
Tassos Gianakakos
Chief Executive Officer, Director, and Chair
Brianne Puglisi
Chief Financial Officer
Jay Edelberg
Chief Medical Officer
Andy Pasternak
Chief Strategy Officer
John B. Moriarty, Jr.
Chief Legal Officer and Corporate Secretary
Paul Berns
Director
Douglas Giordano
Director
David Meeker, M.D.
Director
Kim Popovits
Director
Tim Walbert
Director
Listing date
Jun 18, 2026
Sector
Healthcare